X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Americas

Cerus And Kedrion Biopharma Enter Distribution Agreement For The Full INTERCEPT Blood System Portfolio In Italy

Yuvraj_pawp by Yuvraj_pawp
1st November 2017
in Americas, News

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Cerus Corporation announced that it has entered into an agreement with Kedrion Biopharma to distribute the full complement of INTERCEPT Blood System products in Italy. Kedrion Biopharma will initially distribute INTERCEPT for platelets and plasma and will have the right to distribute INTERCEPT red blood cells following CE mark approval.

Under the terms of the agreement, Kedrion Biopharma will be the sole distributor for the INTERCEPT Blood Systems in Italy and will be responsible for promotion, sales, deployment, and red cell introduction for INTERCEPT in the future.

“We are pleased to be working with Kedrion,” said Gualtiero Garlasco, general manager of Cerus Europe B.V. “Kedrion has significant experience in the plasma derivatives business and understands the dynamics of the Italian transfusion medicine market. We believe Kedrion is the right partner for us as we seek to increase our market presence in Southern Europe given their industry expertise, commercial reach, and strong relationships with blood centers and hospitals in Italy.”

Cerus estimates the Italian transfusion market at approximately 200,000 units for platelets, 400,000 units for plasma, and 2,500,000 units for red blood cells.

“Cerus’ INTERCEPT Blood Systems’ platform complements our current product portfolio and we believe the market opportunity for pathogen inactivation of transfused blood components in Italy is significant. We look forward to working with Cerus to help make INTERCEPT the standard of care in Italy for improving the safety of transfusion medicine and are excited to be collaborating on the potential introduction of the INTERCEPT red cell system,” commented Danilo Medica, Italy Country Manager of Kedrion Biopharma.

INTERCEPT Blood Systems is designed to reduce the transfusion-transmitted infection risk by inactivating a broad range of pathogens including chikungunya. Clusters of chikungunya have been reported by the European Centre for Disease Prevention and Control (ECDC) including the recent outbreak in the Lazio region of Italy which resulted in a temporary halt of blood donations in Rome. Chikungunya is often spread by the bite of Aedes mosquito. Chikungunya outbreaks in Europe have been previously reported in Italy (2007) and France (2010, 2014, and 2017).

ABOUT KEDRION BIOPHARMA
Kedrion Biopharma is an international company that collects and fractionates blood plasma to produce and distribute plasma-derived therapeutic products for use in treating and preventing serious diseases, disorders and conditions such as hemophilia, primary immune system deficiencies and Rh-sensitization.

With over 2,300 employees and a commercial presence in around 100 countries worldwide, Kedrion works to maintain excellent industry standards and aspires to ongoing improvement in order to retain a leading position in Italy and to increase its share of the international markets. The company works to strengthen its role as the accredited partner of medical, scientific and institutional communities, and its ambition is to enhance its worldwide role as a strategic partner of the national health systems of countries, aiming to become self-sufficient in providing plasma-derived products, also via technology transfer.

Additional information about Kedrion Biopharma can be found at www.kedrion.com

ABOUT CERUS
Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.

Tags: America
Previous Post

ORIC Pharma begins phase 1 study of novel GR antagonist with planned development for oncology

Next Post

Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post

Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th American Society of Hematology (ASH) Annual Meeting

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In